Studies have shown that reduced ASS1 expression is associated with aggressive tumor behavior and worse prognosis in various cancers including hepatocellular carcinoma, myxofibrosarcomas, bladder cancer, and nasopharyngeal carcinoma 14, 15, 39, 40. Here, ASS1 is linked to urinary bladder cancer.